期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 9, 期 -, 页码 5123-5133出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S86764
关键词
doxorubicin; anti-CD22 antibody; drug delivery system; target selection; non-Hodgkin lymphoma
资金
- National Nature Science Foundation of People's Republic of China [81201704]
- Science and Technology Development Funds Key Program of Jiangsu Province
The objective of this study was to investigate the anticancer efficacy of dimercaptosuccinic acid-modified iron oxide magnetic nanoparticles coloaded with anti-CD22 antibodies and doxorubicin (anti-CD22-MNPs-DOX) on non-Hodgkin's lymphoma cells. The physical properties of anti-CD22-MNPs-DOX were studied and its antitumor effect on Raji cells in vitro was evaluated using the Cell Counting Kit-8 assay. Furthermore, cell apoptosis and intracellular accumulation of doxorubicin were determined by flow cytometry. The results revealed that anti-CD22-MNPs-DOX inhibited the proliferation of Raji cells, significantly increased the uptake of doxorubicin, and induced apoptosis. Therefore, it was concluded that a coloaded antibody and chemo-therapeutic drug with magnetic nanoparticles might be an efficient targeted treatment strategy for non-Hodgkin's lymphoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据